EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates

Mayumi Sue, Takuya Tsubaki, Yoko Ishimoto, Shinko Hayashi, Saori Ishida, Takafumi Otsuka, Yoshitaka Isumi, Yumi Kawase, Junko Yamaguchi, Takashi Nakada, Jun Ishiguro, Kensuke Nakamura und 5 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0304985 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Mayumi Sue und 16 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Research Laboratories II, Daiichi Sankyo Co., Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: CD47 Antigen, Receptors, Immunologic, Immunoconjugates, Antigens, Differentiation. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daiichi Sankyo Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Signal regulatory protein alpha (SIRPα) is an immune inhibitory receptor on myeloid cells including macrophages and dendritic cells, which binds to CD47, a ubiquitous self-associated molecule. SIRPα-CD47 interaction is exploited by cancer cells to suppress anti-tumor activity of myeloid cells, therefore emerging as a novel immune checkpoint for cancer immunotherapy. In blood cancer, several SIRPα-CD47 blockers have shown encouraging monotherapy activity. However, the anti-tumor activity of SIRPα-CD47 blockers in solid tumors seems limited, suggesting the need for combination therapies to fully exploit the myeloid immune checkpoint in solid tumors. Here we tested whether combination of SIRPα-CD47 blocker with antibody-drug conjugate bearing a topoisomerase I inhibitor DXd (DXd-ADC) would enhance anti-tumor activity in solid tumors. To this end, DS-1103a, a newly developed anti-human SIRPα antibody (Ab), was assessed for the potential combination benefit with datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan (T-DXd), DXd-ADCs targeting human trophoblast cell-surface antigen 2 and human epidermal growth factor receptor 2, respectively. DS-1103a inhibited SIRPα-CD47 interaction and enhanced antibody-dependent cellular phagocytosis of Dato-DXd and T-DXd against human cancer cells. In a whole cancer cell vaccination model, vaccination with DXd-treated cancer cells led to activation of tumor-specific T cells when combined with an anti-mouse SIRPα (anti-mSIRPα) Ab, implying the benefit of combining DXd-ADCs with anti-SIRPα Ab on anti-tumor immunity. Furthermore, in syngeneic mouse models, both Dato-DXd and T-DXd combination with anti-mSIRPα Ab showed stronger anti-tumor activity over the monotherapies. Taken together, this study provides a preclinical rationale of novel therapies for solid tumors combining SIRPα-CD47 blockers with DXd-ADCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD47 AntigenReceptors, ImmunologicImmunoconjugatesAntigens, DifferentiationAnimalsHumansMiceCell Line, TumorFemaleTrastuzumabTopoisomerase I InhibitorsImmunotherapyMice, Inbred BALB C

Substanzen

CD47 AntigenReceptors, ImmunologicImmunoconjugatesAntigens, DifferentiationSIRPA protein, humanTrastuzumabCD47 protein, humanTopoisomerase I Inhibitors

Autor:innen und Institutionen

  • Discovery Research Laboratories II, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • Modality Research Laboratories III, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • Translational Science Department I, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • Research Innovation Planning Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • Discovery Research Laboratories V, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • Discovery Research Laboratories I, Daiichi Sankyo Co., Ltd., Tokyo, Japan.

ORCID-Profile: Norihito Kawasaki

Förderung

  • Daiichi Sankyo Company

Zitieren

APA

Sue, M., Tsubaki, T., Ishimoto, Y., Hayashi, S., Ishida, S., Otsuka, T., Isumi, Y., Kawase, Y., Yamaguchi, J., Nakada, T., Ishiguro, J., Nakamura, K., Kawaida, R., Ohtsuka, T., Wada, T., Agatsuma, T., & Kawasaki, N. (2024). Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates. PLOS ONE. https://doi.org/10.1371/journal.pone.0304985

Vancouver

Sue M, Tsubaki T, Ishimoto Y, Hayashi S, Ishida S, Otsuka T, et al. Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates. PLOS ONE. 2024. doi:10.1371/journal.pone.0304985

BibTeX
@article{Sue2024,
  author = {Sue, Mayumi and Tsubaki, Takuya and Ishimoto, Yoko and Hayashi, Shinko and Ishida, Saori and Otsuka, Takafumi and Isumi, Yoshitaka and Kawase, Yumi and Yamaguchi, Junko and Nakada, Takashi and Ishiguro, Jun and Nakamura, Kensuke and Kawaida, Reimi and Ohtsuka, Toshiaki and Wada, Teiji and Agatsuma, Toshinori and Kawasaki, Norihito},
  title = {Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0304985}
}
Kostenlos starten →